Unexpected cardiovascular risks of glucagon‐like peptide‐1 receptor agonist and aspirin co‐administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched cohort study
Authors' conclusion
The combination of GLP-1 RAs with aspirin in individuals with obesity, both with and without T2D, was associated with increased cardiovascular risks compared to GLP-1 RA monotherapy. These findings suggest that there may be risks associated with the combined use of these treatments and highlight the need for further research into this possible complication with regard to treatment.
Study context
- Population
- Individuals with obesity, with and without T2D (four matched groups: diabetic and non-diabetic)
- Participants
- 2,946,579 individuals
- Exposure
- GLP-1 RA plus aspirin vs GLP-1 RA alone
- Outcome
- Cardiovascular outcomes and adverse events
- Follow-up
- 5 years
Methodological detailsTriNetX US and Global dataset
- TriNetX US and Global dataset
Main finding
As reported in the abstract
Cardiovascular events
GLP-1 RA + aspirin vs GLP-1 RA aloneHazard ratio (95% CI)
Hypertensive heart diseases, non-diabetic
1.40(1.15–1.60)
Ischaemic heart disease, non-diabetic
2.39(1.92–2.97)
HF, non-diabetic
1.97(1.54–2.53)
Observational data: associations, not effects.
Original publication
Unexpected cardiovascular risks of glucagon‐like peptide‐1 receptor agonist and aspirin co‐administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched cohort study. Diabetes Obes Metab. Published 13 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →